Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Official title: NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
360
Start Date
2026-04
Completion Date
2029-12
Last Updated
2026-03-31
Healthy Volunteers
No
Interventions
LY4584180
administered orally
Rituximab
administered through IV infusion
Locations (44)
Mayo Clinic - Scottsdale
Scottsdale, Arizona, United States
City of Hope
Duarte, California, United States
University of California, Los Angeles (UCLA) - Medical Center
Los Angeles, California, United States
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
University of Miami - Sylvester Cancer Center
Miami, Florida, United States
Florida Cancer Specialists - Sarasota
Sarasota, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Columbia University
New York, New York, United States
University of Rochester
Rochester, New York, United States
The Ohio State University (OSU)
Columbus, Ohio, United States
Oregon Health & Science University (OHSU)
Portland, Oregon, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Texas Oncology - DFW (Sammons CC)
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)
Seattle, Washington, United States
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
CHU de Nantes - Hotel-Dieu
Nantes, France
Institut Curie
Paris, France
CHU Bordeaux - Hopital Haut-Leveque - Centre Francois Magendie
Pessac, France
HCL Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Oncopole Claudius Regaud
Toulouse, France
Charite Universitaetsmedizin Berlin
Berlin, Germany
Universitaetsklinikum Koeln (AoeR)
Cologne, Germany
Universitaetsklinikum Essen
Essen, Germany
Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet
Frankfurt am Main, Germany
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
Bologna, Italy
Istituto Europeo di Oncologia
Milan, Italy
National Cancer Center Hospital East
Chiba, Japan
Cancer Institute Hospital of JFCR
Tokyo, Japan
Pratia Onkologia Katowice
Katowice, Poland
Pratia MCM Krakow
Krakow, Poland
AIDPORT Sp. z o.o.
Skorzewo, Poland
Instytut Hematologii i Transfuzjologii w Warszawie
Warsaw, Poland
Institut Catala d'Oncologia - L'Hospitalet
Barcelona, Spain
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid, Spain
King's College Hospital
London, United Kingdom
Nottingham City Hospital
Nottingham, United Kingdom
Derriford Hospital
Plymouth, United Kingdom
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom